Awards

$211K

Engineering of Human Corneal Endothelial Grafts

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 06/01/12 - 05/31/13
PI: Ying Ting Zhu

DESCRIPTION (provided by applicant): The corneal endothelium plays a pivotal role in maintaining corneal transparency. Unlike other species, the human corneal endothelium is notorious for its limited proliferative capacity in vivo after injury, aging, and surgery. Persistet corneal endothelial dysfunction leads to sight- threatening bullous kera...

$240K

Anti-angiogenesis of HC-HA Covalent Complex and PTX3 Purified from Fetal Membrane

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 07/01/11 - 06/30/13
PI: Scheffer C G Tseng

DESCRIPTION (provided by applicant): Angiogenesis is a part of adult wound healing, which starts from inflammation and may end in scarring. When inflammation, angiogenesis, and scarring are well controlled, adult wound healing results in the restoration of tissue function. In contrast, pathologic angiogenesis that is frequently associated with u...

$497K

Phase II: Anti-inflammatory and Anti-scarring Actions of Amniotic Membrane Extra

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 06/01/11 - 05/31/13
PI: Scheffer C G Tseng

DESCRIPTION (provided by applicant): Over the past decade, there has been a surge of interest in amniotic membrane transplantation (AMT) for ocular surface reconstruction. A number of studies have shown that AMT using cryopreserved AM (AmnioGraft(R)) manufactured by Bio-Tissue, Inc., a subsidiary of TissueTech, Inc., is effective in facilitating...

$438K

Phase II: Anti-inflammatory and Anti-scarring Actions of Amniotic Membrane Extra

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 06/01/10 - 05/31/11
PI: Scheffer C G Tseng

DESCRIPTION (provided by applicant): Over the past decade, there has been a surge of interest in amniotic membrane transplantation (AMT) for ocular surface reconstruction. A number of studies have shown that AMT using cryopreserved AM (AmnioGraft(R)) manufactured by Bio-Tissue, Inc., a subsidiary of TissueTech, Inc., is effective in facilitating...

$132K

Amniotic Membrane Patch Graft to Cover Glaucoma Drainage Tube

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 09/01/09 - 08/31/10
PI: Sheha Hosam El

DESCRIPTION (provided by applicant): Glaucoma drainage devices (GDDs) have widely been used in the treatment of high risk refractory glaucoma. To avoid tube exposure, which may lead to serious eye infection, the implanted GDD tube has to be covered by a patch graft made of donor sclera or pericardium. However, such a patch graft still carries a ...

$112K

Tea Tree Oil for Treating Ocular Demodex Infestation

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 07/01/09 - 06/30/10
PI: Scheffer C G Tseng

DESCRIPTION (provided by applicant): Demodex (folliculorum and brevis) mites are microscopic ectoparasites that commonly infest the pilosebaceous unit of the skin. Uncontrolled overgrowth of these mites has been implicated in causing rosacea in the face, blepharitis in the eyelid, and other inflammation-associated conjunctival and corneal abnorm...

$368K

Development of Sutureless Amniotic Membrane Graft

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/07 - 08/31/09
PI: Scheffer C G Tseng

DESCRIPTION (provided by applicant): Due to the Principal Investigator's pioneering work over the past decade, amniotic membrane transplantation (AMT) for ocular surface reconstruction was approved by the FDA in 2001 and reimbursed by Medicare in 2004 as a standard surgical procedure. A number of studies have shown that AMT is effective in facil...

$113K

Anti-scarring and Anti-inflammatory Effects of Amniotic Membrane Extracts

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/15/06 - 02/28/08
PI: Scheffer C G Tseng

DESCRIPTION (provided by applicant): Due to the Pi's pioneering work over the past decade, amniotic membrane transplantation (AMT) for ocular surface reconstruction was approved by the FDA in 2001 and reimbursed by Medicare in 2004 as a standard surgical procedure. A number of studies have shown that AMT is effective in facilitating epithelial w...

$362K

Development of Sutureless Amniotic Membrane Graft

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/06 - 08/31/07
PI: Scheffer C G Tseng

DESCRIPTION (provided by applicant): Due to the Principal Investigator's pioneering work over the past decade, amniotic membrane transplantation (AMT) for ocular surface reconstruction was approved by the FDA in 2001 and reimbursed by Medicare in 2004 as a standard surgical procedure. A number of studies have shown that AMT is effective in facil...

$117K

Ex Vivo Expansion of Rpe Cells for Transplantation

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/01/05 - 01/31/07
PI: Scheffer C G Tseng

Retinal pigment epithelial cells (RPE) play a pivotal role in maintaining retinal function. Dysfunction of RPE contributes to the pathogenesis of age-related macular degeneration (ARMD), which accounts for the major cause of permanent visual loss after age 55 years in Western countries. Conventional treatment such as laser photocoagulation has a...

Load More